Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet syndrome ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...